You are here: > Resources > Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ)

Self Description

February 2005: "Johnson & Johnson is the world's most comprehensive and broadly based manufacturer of health care products, as well as a provider of related services, for the consumer, pharmaceutical and medical devices and diagnostics markets. Johnson & Johnson has more than 200 operating companies in 57 countries around the world employing 109,900 employees and selling products in more than 175 countries. The fundamental objective of Johnson & Johnson is to provide scientifically sound, high quality products and services to help heal, cure disease and improve the quality of life. This is a goal that began with the Company's founding in 1886.

In 1943 Robert Wood Johnson wrote Our Credo, a one-page document that outlines our responsibilities to our customers, employees, the community and shareholders. The Credo is available in 36 languages on this Web site. Johnson & Johnson's adherence to the ethical principles embodied in the Credo have resulted in numerous awards and accolades which recognize the company as an employer and a good corporate citizen."

Third-Party Descriptions

April 2012: "A number of companies have already handed over large fines. Last April, Johnson & Johnson paid $78 million to settle claims that it violated the UN's Oil for Food program."

May 2011: "In recent years, big makers of implants like heart devices and artificial joints, including Johnson & Johnson, Boston Scientific and St. Jude Medical, have settled Justice Department charges that they illegally promoted sales. The enforcement effort has sought to reduce the role of corporate influence over medicine through tactics like bogus or inflated consulting deals with doctors."

December 2010: "Until late summer, officials at the Johnson & Johnson unit, DePuy Orthopaedics, the largest maker of replacement hips worldwide, maintained that the A.S.R. was performing on a par with competing devices. But interviews with doctors indicate that DePuy received repeated warnings that the implant was failing and that surgeons were abandoning it."

May 2010: "The Johnson & Johnson unit that recalled millions of bottles of liquid children’s Tylenol and other pediatric medicines last month may face criminal penalties, product seizures or other sanctions, an official from the Food and Drug Administration said Thursday."

April 2009: 'What do Procter & Gamble (PG), Johnson & Johnson (JNJ), Verizon (VZ), and General Mills (GIS) have in common? All are pouring more advertising dollars into marketing aimed at Hispanics. Last year, General Mills tripled its spending on commercials on Spanish-language TV to more than $35 million, according to ad tracker TNS Media Intelligence. "We've gone aggressively into Hispanic marketing," explains the food company's Chief Marketing Officer Mark Addicks, "because we're getting double-digit sales gains."'

May 2008: 'This would provide mentors and role models as well as alter the gender landscape. The program at Johnson & Johnson, called “Crossing the Finish Line,” tutors women in leadership skills.'

May 2008: "The 60-second ad for the Cypher stent, made by the Cordis subsidiary of Johnson & Johnson, failed to adequately warn consumers about the potential dangers of receiving a stent, according to the article published by the New England Journal of Medicine."

October 2007: "The law did not require Johnson & Johnson to take such measures, but by doing so, the company earned the respect of consumers and the media alike, and this case is now widely taught in business schools as an example of how to manage a crisis effectively—and continue to prosper. Those seven who died can never be brought back, but J&J took extraordinary steps to ensure that no one else would be in jeopardy. Here we are, 25 years after the fact, still talking about how the company conducted itself admirably. (Disclosure: Several years ago, I gave a few speeches that were sponsored by Vistakon, a subsidiary of Johnson & Johnson.)"

August 2007: "The dispute over rights to the symbol erupted to the surface yesterday in federal court in Manhattan, where J.& J. sued the American Red was not clear how far the American Red Cross wanted to go in licensing the symbol for commercial purposes, noting that the red cross was a trademark of Johnson & Johnson before the American Red Cross was officially chartered.

May 2007: Just as surprising, Ms. Bailey said, was learning that the university psychiatrist who supervised Anya’s care received more than $7,000 from 2003 to 2004 from Johnson & Johnson, Risperdal Johnson, Risperdal’s maker, in return for lectures about one of the company’s drugs.

January 2007: Twenty-seven members of the pharmaceutical manufacturers organization have endorsed the guidelines, but it is hard to figure exactly how long the delays in advertising will run. Bristol-Myers Squibb has said that it would delay for 12 months. Johnson & Johnson and Pfizer said they would wait six months. The manufacturers group cannot say how other companies have interpreted the guidelines, a spokesman said.

December 2006: The issue also has major financial implications, with worldwide sales of drug-eluting stents now estimated at about $6 billion annually. Boston Scientific Corp. and Johnson & Johnson, which make the two drug-eluting stents sold in the United States, defend the safety of the devices.

August 2006: In October 2000, nearly 300 former inmates sued the University of Pennsylvania, Dr. Kligman, Dow Chemical and Johnson Dow Chemical and Johnson & Johnson for injuries they said occurred during the experiments at Holmesburg, but the suit was dismissed because the statute of limitations had expired.

January 2006: ...Johnson & Johnson in 1999 provided an 'educational' grant to pay for an alumni reception at the annual meeting of a medical specialty society. That grant was provided at the request of a physician who had previously received grant money for research and educational activities related to Propulsid, a Johnson & Johnson drug that was withdrawn in 2000...

November 2005: McNeil Consumer & Specialty Pharmaceuticals, a division of Johnson & Johnson, updated the labeling on all its Tylenol products in 2002 to list all the active ingredients on the front of the bottle, increase the type size of acetaminophen, and added a label on the front warning consumers not to use the product with others that contain acetaminophen, said Kathy Fallon a spokeswoman.


RoleNameTypeLast Updated
Opponent (past or present) American National Red Cross, The (American Red Cross) Organization Aug 10, 2007
Owner of (partial or full, past or present) Centocor Organization Feb 21, 2005
Owner of (partial or full, past or present) Cordis Corporation Organization Jun 28, 2006
Owner of (partial or full, past or present) DePuy Organization Jan 25, 2006
Owner of (partial or full, past or present) Janssen Pharmaceuticals Organization Jan 12, 2014
Owner of (partial or full, past or present) Janssen Organization May 24, 2006
Owner of (partial or full, past or present) McNeil Consumer Healthcare Organization Mar 13, 2011
Owner of (partial or full, past or present) McNeil Laboratories Organization Mar 13, 2011
Owner of (partial or full, past or present) Neutrogena Organization Nov 22, 2007
Owner of (partial or full, past or present) Ortho-McNeil Pharmaceutical Organization Mar 13, 2011
Owner of (partial or full, past or present) Scios Organization Jun 28, 2006
Organization Head/Leader (past or present) Colleen A. Goggins M.M. Person May 28, 2010
Organization Head/Leader (past or present) Founded/Co-Founded by Robert Wood Johnson Person Aug 10, 2006
Organization Head/Leader (past or present) William C. Weldon Person Mar 13, 2011

Articles and Resources

36 Articles and Resources. Go to:  [Next 16]

Date Resource Read it at:
Apr 26, 2012 Not just Wal-Mart: Dozens of U.S. companies face bribery charges

QUOTE: Deere, Disney, Hewlett-Packard, Qualcom and many others are also under investigation for violations of the U.S. Foreign Corrupt Practices Act.

CNN (Cable News Network)
May 31, 2011 Sales Tactics on Implants Raise Doubts

QUOTE: an implant industry where producers seek to influence the brand of device that patients receive long before a diagnosis....big makers of implants like heart devices and artificial joints, including Johnson & Johnson, Boston Scientific and St. Jude Medical, have settled Justice Department charges that they illegally promoted sales. The enforcement effort has sought to reduce the role of corporate influence over medicine through tactics like bogus or inflated consulting deals with doctors.

New York Times
Mar 10, 2011 U.S. Regulators and J.&J. Unit Reach a Deal on Plant Oversight

QUOTE: Federal regulators reached an agreement on Thursday with a unit of Johnson & Johnson that would impose greater federal oversight at three manufacturing plants responsible for recalls of children’s Tylenol and many other popular over-the-counter medicines... Last year, the company’s (Johnson & Johnson) DePuy unit recalled two different hip implants, affecting tens of thousands of patients worldwide. Its Animas unit recalled tens of thousands of insulin pump cartridges last month because they had the potential to leak and deliver too little insulin, the company said.

New York Times
Dec 16, 2010 The Implants Loophole

QUOTE: The brief and troubled life of DePuy’s A.S.R. hip points to a medical implant system that is piecemeal and broken on many fronts, critics say. Unlike new drugs, many of which go through a series of clinical trials before receiving approval from the Food and Drug Administration, critical implants can be sold without such testing if a device, like an artificial hip, resembles an implant already approved and used on patients.

New York Times
May 27, 2010 F.D.A. Weighs Penalties in Drug Recall

QUOTE: [The FDA] is considering further actions against McNeil Consumer Healthcare, the Johnson & Johnson unit, after a pattern of violations in manufacturing and quality control practices led to a number of recent recalls...

New York Times
Jul 22, 2009 White House declines to disclose visits by health industry executives

QUOTE: Invoking an argument used by President George W. Bush, the Obama administration has turned down a request from a watchdog group for a list of health industry executives who have visited the White House...

Los Angeles Times
Apr 12, 2009 U.S. Marketers Say Hola! to Hispanic Consumers

QUOTE: All are pouring more advertising dollars into marketing aimed at Hispanics....America's 45.5 million Hispanics have been particularly hard hit since the U.S. economy went off the rails. Unemployment among Hispanics shot up in March to 11.4%, the Bureau of Labor Statistics reports, compared with 8.5% for the U.S. population as a whole. But Hispanic consumers are less likely to be hobbled by mortgage or credit-card debt, and tend to have two or more income earners in a household, according to market researcher Experian Simmons.

Jun 07, 2008 Child Experts Fail to Reveal Full Drug Pay

QUOTE: By failing to report income, the psychiatrist, Dr. Joseph Biederman, and a colleague in the psychiatry department at Harvard Medical School, Dr. Timothy E. Wilens, may have violated federal and university research rules designed to police potential conflicts of interest, according to Senator Charles E. Grassley, Republican of Iowa. Some of their research is financed by government grants.

New York Times
May 15, 2008 Diversity Isn’t Rocket Science, Is It? (Life's Work)

QUOTE: “It’s almost a time warp,” said Sylvia Ann Hewlett, the founder of the Center for Work-Life Policy, a nonprofit organization that studies women and work. “All the predatory and demeaning and discriminatory stuff that went on in workplaces 20, 30 years ago is alive and well in these professions.”

New York Times
May 14, 2008 Medical Journal’s Article Questions TV Ads for Stent

QUOTE: “We believe that the F.D.A. should perform a critical post-release review of the ‘Life Wide Open’ campaign to assess whether it meets the basic regulatory requirements for non-deceptive advertising,” the journal’s commentary said. It also questioned the validity of advertising such high-risk procedures directly to the public.

New York Times
Mar 16, 2008 Cutting Dosage of Costly Drug Spurs a Debate

QUOTE: In that sense, the dispute over Cerezyme could be a sign of the increased scrutiny that dosing will receive as drugs become more expensive. Pharmaceutical companies have faced complaints for years over prices, but now they might have to defuse efforts to use less of their drugs to cut costs, and to rebut accusations that doses are inflated to bolster profits.

New York Times
Oct 15, 2007 If It's Legal, It's Ethical…Right?

QUOTE: The recent case of a TV crew allowing a woman to drive while drunk reminds us, when the law falls short, refer to the higher authority of ethics

Aug 09, 2007 Johnson & Johnson Sues Red Cross Over Symbol

QUOTE: The dispute over rights to the symbol erupted to the surface yesterday in federal court in Manhattan, where J.& J. sued the American Red Cross.

New York Times
Jul 10, 2007 Doctors Balk at Cancer Ad, Citing Lack of Evidence

QUOTE: the advertisement’s implicit message — that those who die of skin cancer have themselves to blame — has provoked a sharp response from some public-health doctors, who say the evidence simply does not support it.

New York Times
Jun 15, 2007 Are Pharmas Addicted to Lifestyle Drugs?: Drugmakers are eager to spiff up your sex life and hairline, even as their lucrative products face mounting safety questions

QUOTE: Try as they might to distance themselves from the lifestyle drug sector, pharmaceutical companies can't seem to kick their addiction to these lucrative products. Even as consumers and government regulators grow more alarmed over drug safety, an examination of four popular lifestyle categories—weight loss, hair loss, sleep, and sexual dysfunction—shows that the pharmaceutical industry is by no means shying away from this controversial territory.

May 10, 2007 Psychiatrists, Children and Drug Industry’s Role

QUOTE: "But the intersection of money and medicine, and its effect on the well-being of patients, has become one of the most contentious issues in health care. Nowhere is that more true than in psychiatry, where increasing payments to doctors have coincided with the growing use in children of a relatively new class of drugs known as atypical antipsychotics."

New York Times
Jan 22, 2007 Showdown Looms in Congress Over Drug Advertising on TV

QUOTE: "Criticism of direct-to-consumer advertising has intensified since 2004, after Merck withdrew Vioxx, a heavily advertised painkiller, after a clinical trial showed that it sharply increased the risk of heart attacks and strokes."

New York Times
Jan 18, 2007 The spread of the credit check as civil rights issue: Minorities are starting to fight employers over the use of credit history in hiring.

QUOTE: Some privacy and minority advocates are now seeing credit as a civil rights issue as minorities start to fight employers and insurers who base decisions on credit histories. Their effort could slow the near doubling in credit checks by employers in the past decade, which impacts millions of Americans who are struggling with debt. "It's definitely a civil rights issue because of the growing use of credit reports and credit scores for hiring, renting an apartment, insurance, and the fact that people of color have not been integrated into the credit scoring system as much as traditional, white, middle-class America"...

Christian Science Monitor
Dec 06, 2006 New Artery Stents Raise Safety Concerns

QUOTE: "A flurry of recent research has raised alarm about the safety of a new generation of stents that have quickly become the most commonly used devices for treating clogged arteries, creating widespread concern about how to care for millions of heart-disease patients."

Washington Post
Sep 01, 2006 California Plan to Cut Gases Splits Industry

QUOTE: While high-technology companies have lined up behind the move, arguing that it will put California at the forefront of alternative energy development, most of those representing basic industries contend that it will retard the economy, force energy-intensive businesses out of state and increase costs for all Californians.

New York Times

36 Articles and Resources. Go to:  [Next 16]